Cognitive Disorders in Patients with Parkinson's Disease

Keywords: Parkinson's disease, cognitive impairment, quality of life


The aim of the study was to identify cognitive disorders in patients with Parkinson's disease

Material and methods. The study was conducted on the basis of the neurological department of the Regional Clinical Hospital (Odesa) during 2011-2021. 364 patients were diagnosed with Parkinson disease (PD) on the basis of diagnostic criteria of the British Brain Bank. Clinical and demographic data were studied: age, sex, severity according to the UPDRS scale, stage of the disease according to the Hoen-Yahr scale, the presence of cognitive impairment and their nature. MMSE (Mini-Mental State Examination;) and PD-CRS (Parkinson’s Disease-Cognitive Rating Scale) were used to study cognitive functions. Statistical processing was performed by analysis of variance, correlation and factor analysis using Statistica 13.0 software (TIBCO, USA).


At the onset of the disease, left lesions were noted in 126 of 364 patients, ie 34.6%, right - 127 (34.9%), the remaining 111 (30.5%) - bilateral lesions. The structure of the disease was dominated by mixed forms. Akinetic-rigid form was observed in 92 (25.3%) cases, trembling - in 27 (7.4%), mixed rigid-trembling in 157 (43.1%) cases, trembling-rigid in 92 (7.4%). Patients with stage 2 and 3 CP were most often registered in 28.6% and 28.0% of cases, respectively. 31 (8.5%) patients had more severe motor disorders (stages 3.5 and 4). Cognitive impairment was detected in a significant number of patients (238 or 45.2%), the mean score on the MMSE scale was 25.3 ± 0.3. Accordingly, on the PD-CRS scale, the average score was 91.2 ± 3.4 points. Subdemental changes were present in 82 (15.6%) patients. Accordingly, mild dementia was found in 15 (2.8%) patients, moderate dementia - in 18 (3.4%).


  1. The frequency of detection of cognitive impairment in patients with CP was 45.2% with a mean score on the MMSE scale of 25.3 ± 0.3, and on the PD-CRS scale - 91.2 ± 3.4 points
  2. Dementia changes were in 82 (15.6%) patients, mild dementia was found in 15 (2.8%) patients, moderate dementia - in 18 (3.4%)
  3. There is a direct correlation between the age and severity of intellectual disabilities (r = 0.50).
  4. Self-care disorders are determined by the severity of both motor and cognitive disorders by 72% (R = 0.851; R2 = 0.723; Adjusted R2 = 0.721; F (2.2) = 309; p <10-4; SE = 4.6 ).

Key words: Parkinson's disease, cognitive impairment, quality of life


Trufanov Y., Svyrydova N., Galusha A., Svistun V., Harkava I., Bondarenko H., Zhhilova N. New epidemiological data of Parkinson's Disease in Ukraine [abstract]. Mov Disord. 2019; 34 (suppl 2). Accessed April 28, 2022.

Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020 Feb;36(1):1-12. Epub 2019 Aug 24. PMID: 31733690; PMCID: PMC6905381. Available from:

Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808. Epub 2020 Jun 23. PMID: 32576618. Available from:

Chia SJ, Tan EK, Chao YX. Historical Perspective: Models of Parkinson's Disease. Int J Mol Sci. 2020 Apr 2;21(7):2464. PMID: 32252301; PMCID: PMC7177377. Available from:

Barone P, Erro R, Picillo M. Quality of Life and Nonmotor Symptoms in Parkinson's Disease. Int Rev Neurobiol. 2017;133:499-516. Epub 2017 Jul 15. PMID: 28802930. Available from:

Roheger M, Kalbe E, Liepelt-Scarfone I. Progression of Cognitive Decline in Parkinson's Disease. J Parkinsons Dis. 2018;8(2):183-193. PMID: 29914040; PMCID: PMC6004891. Available from:

Ding W, Ding LJ, Li FF, Han Y, Mu L. Neurodegeneration and cognition in Parkinson's disease: a review. Eur Rev Med Pharmacol Sci. 2015 Jun;19(12):2275-81. PMID: 26166654.

Bloem BR, Eimers M, van Galen MS, Munneke M, Darweesh SKL. From trials to clinical practice: Temporal trends in the coverage of specialized allied health services for Parkinson's disease. Eur J Neurol. 2021 Mar;28(3):775-782. Epub 2020 Dec 2. PMID: 33141474; PMCID: PMC7898913. Available from:

Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021 Jun 12;397(10291):2284-2303. Epub 2021 Apr 10. PMID: 33848468. Available from:

Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021 Jul 1;7(1):47. Erratum in: Nat Rev Dis Primers. 2021 Jul 13;7(1):53. PMID: 34210995. Available from:

Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort. J Neurol. 2019 Aug;266(8):1927-1936. Epub 2019 May 9. PMID: 31073716; PMCID: PMC6647182. Available from:

Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB; MDS Task Force on the Definition of Parkinson's Disease. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2019 Oct;34(10):1464-1470. Epub 2019 Aug 14. PMID: 31412427. Available from:

Trivedi D. Cochrane Review Summary: Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Prim Health Care Res Dev. 2017 Nov;18(6):527-528. Epub 2017 Jun 5. PMID: 28578720. Available from:

Fernández-Bobadilla R, Martínez-Horta S, Marín-Lahoz J, Horta-Barba A, Pagonabarraga J, Kulisevsky J. Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS). Parkinsonism Relat Disord. 2017 Oct;43:73-77. Epub 2017 Jul 19. PMID: 28754233. Available from:

TIBCO Statistica® 13.3.0 Retrieved from:

Original Research